samedan logo
 
 
 
spacer
home > ebr > autumn 2017 > homing in
PUBLICATIONS
European Biopharmaceutical Review

Homing In

Since the first daVinci surgical systems began marketing in 1999 and the following acquisition of Computer Motion by Intuitive Surgical in 2003, very few innovations have been made in the field. Initial adoption of such technology was limited and most surgeons were highly sceptical about its future. However, over the span of 15 years, Intuitive Surgical transformed robotic surgery from an interesting market experiment to an established technique. Today, analysts project exponential growth in the years to come, and nobody doubts that the future is in robotics.

As initial patents expire and new technologies are developed, a rising number of modern robotic surgical systems have been, or are about to be, launched. The competition for shares will be fierce.

Perfecting Platforms

The market might seem big enough for everybody, but the reality could be more complex. For most hospitals, adopting a given robotic surgical platform is a big decision and is not easily reversible, as it involves significant costs and efforts, such as staff training. Due to the requirements for an increased number of operating rooms and storage, a costly multi-platform-adapted staff and a complex maintenance organisation, working with two different types of robotic platforms is also unlikely. However, bigger hospitals that might actually need to utilise several robotic platforms could reduce costs by taking advantage of economies of scale.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Dr Andre Faure has a surgical background and decided to interrupt his early medical career to develop new surgical devices. For more than 15 years, he has led several multi-national R&D programmes in the field where he has developed robotic surgical instruments, including devices for treating atrial fibrillation and liver cancer. Andre is also the founder of Trod Medical, a company created around one of his inventions – a robotic device specifically developed for localised prostate cancer treatment.
spacer
Dr Andre Faure
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines

PARIS & OXFORD, England & BOSTON--(BUSINESS WIRE)-- Sanofi and Exscientia announced today a groundbreaking research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscientia’s end-to-end AI-driven platform utilising actual patient samples. The companies have been working together since 2016 and in 2019, Sanofi in-licensed Exscientia’s novel bispecific small molecule candidate capable of targeting two distinct targets in inflammation and immunology.
More info >>

White Papers

Personalised Medicine - Pharma and Dx Firms Share Wider Horizons

DiagnostikNet-BB

Personalised medicine might be a popular catch-phrase at the moment, but the term often causes confusion, as there is still no uniform definition for it. The expression can include areas as diverse as the measurement of individual risk, early detection using biomarker testing, stratification of patients suffering from a disease and predictions about its course.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement